Table 9.6a

Immunosuppression Use for Induction, 1994 to 2003

Recipients with Liver Transplants

	Year of Transplant
	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
Transplants	3,652	3,934	4,080	4,187	4,516	4,749	4,989	5,188	5,330	5,669
Tx With Immunosuppression Info	3,105	3,389	3,531	3,871	4,199	4,431	4,840	5,026	5,197	5,483
No Induction Drugs Recorded	86.7%	85.7%	89.8%	92.9%	91.0%	86.7%	84.5%	84.6%	82.7%	79.5%
Drugs	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
ALG
ATG/NRATG/NRATS	4.6%	4.5%	3.7%	2.1%	1.2%	0.7%	0.7%	0.4%	0.5%	0.5%
OKT3	8.7%	10.0%	6.7%	4.9%	3.6%	1.4%	0.8%	0.7%	0.3%	0.3%
Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.1%	0.5%	1.2%	2.4%	4.2%	6.4%
Zenapax	0.0%	0.0%	0.0%	0.0%	2.9%	6.6%	6.6%	5.9%	4.6%	5.5%
Simulect	0.0%	0.0%	0.0%	0.1%	1.4%	4.4%	6.6%	6.2%	7.8%	7.2%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%

Source: OPTN/SRTR Data as of May 3, 2004.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.